| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T429 |
0-126 |
Sentence |
denotes |
The main clinical feature of ARDS patients is the progressive deterioration of lung function leading to progressive hypoxemia. |
| T430 |
127-313 |
Sentence |
denotes |
ARDS can be induced by different causes such as ZnCl2 aspiration, sepsis, trauma, acute pancreatitis, or pneumonias following virus infections such as SARS-CoVs or human influenza virus. |
| T431 |
314-450 |
Sentence |
denotes |
ACE insertion/deletion polymorphisms correlated with severity of ARDS in humans, suggesting that the RAS could have a role in ARDS [44]. |
| T432 |
451-629 |
Sentence |
denotes |
In animal models, ACE2 protected from acute lung by inhibiting Ang II/AT1R activity [15], for this reason the use of recombinant ACE2 in ARDS has been proposed and pursued [134]. |
| T433 |
630-960 |
Sentence |
denotes |
Clinical trials with recombinant human ACE2 started in healthy volunteers in 2009 (ClinicalTrials.gov number, NCT00886353 [178]), then it was tested in ARDS (ClinicalTrials.gov number, NCT01597635 [134]), PAH (ClinicalTrials.gov number, NCT01884051 [108]) and finally in COVID-19 patients (ClinicalTrials.gov number, NCT04287686). |
| T434 |
961-1059 |
Sentence |
denotes |
Despite its safe use, no conclusive evidence in support of its use in these diseases was reported. |
